Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16

International Journal of Hematology

Volumn 64, Issue 3-4, 1996, Pages 221-229

  Kagami, Yoshitoyo ^a   Ariyoshi, Yutaka ^a   Horiuchi, Atsushi ^b   Kanamaru, Akihisa ^c   Kano, Yasuhiko ^d   Naoe, Tomoki ^e   Oguro, Masao ^f   Ohno, Ryuzo ^g   Sampi, Kazumi ^h   Shirakawa, Shigeru ⁱ   Masaoka, Tohru ^j   Furue, Hisashi ^k  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d TOCHIGI CANCER CENTER   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CHIBA CANCER CENTER   (Japan)

^g HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAITAMA CANCER CENTER   (Japan)

ⁱ MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j CENTER FOR ADULT DISEASES   (Japan)

^k TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

MST 16; Non Hodgkin's lymphoma; Salvage chemotherapy; Topoisomerase II; VP 16

Indexed keywords

ETOPOSIDE; SOBUZOXANE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 10244230907     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/0925-5710(96)00488-4     Document Type: Article

References (25)

1. [1] Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
2. [2] Velasquez WS, McLaughlin P, Tucker S et al. ESHAP -an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-1176.
3. [3] Wilson WH, Bryant G, Bates S et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573-1582.
4. [4] Herbrecht R, Damonte JC, Dufour P et al. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen. Semin Oncol 1992;19:7-10.
5. [5] Narita T, Yaguchi S, Komatsu T et al. Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models. Cancer Chemother Pharmacol 1990;26:193-197.
6. [6] Narita T, Koide Y, Yaguchi S et al. Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine). Cancer Chemother Pharmacol 1991;28:235-240.
7. [7] Narita T, Miyazaki H, Takase M, Inaba M, Tsukagoshi S. Antitumor activity of new antitumor agent, MST-16. Proc Jpn Cancer Assoc 1985;44:929.
8. [8] Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991;51:4903-4908.
9. [9] Ishida R, Miki T, Narita T et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991;51:4909-4916.
10. [10] Furue H, Niitani H, Nakao I et al. Phase I study of MST-16. Jpn J Cancer Chemother 1990;17:1287-1294.
11. [11] Tomonaga N, Teshima H, Hiraoka A et al. Early phase II study of MST-16 (Sobuzoxane) on malignant lymphoma. Jpn J Cancer Chemother 1991;18:2441-2446.
12. [12] Yamada K, Ohno R, Oguri T et al. Late phase II study of MST-16 (Sobuzoxane) on malignant lymphoma. Jpn J Cancer Chemother 1991;18:2447-2452.
13. [13] Masaoka T, Kageyama T, Tatsumi N et al. Late phase II study of MST-16 (Sobuzoxane) efficacy for malignant lymphoma. Jpn J Cancer Chemother 1992;19:339-347.
14. [14] Dombernowsky P, Nissen NI. Schedule dependency of antitumor activity of the podophyllotoxin-derivative VP-16-213 (NSC-141540) in L1210 leukemia. Acta Microbiol Scand A 1973;81:715-724.
15. [15] Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide - A phase I trial. J Clin Oncol 1989;7:396-401.
16. [16] Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase I trial. J Clin Oncol 1990;8:1613-1617.
17. [17] Rowe TC, Tewey KM, Liu LF. Identification of the breakage-reunion subunit of T4 DNA topoisomerase. J Biol Chem 1984;259:9177-9181.
18. [18] Tewey KM, Chen GL, Nelson EM et al. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:9182-9187.
19. [19] Chen GL, Yang L, Rowe TC et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:13560-13566.
20. [20] Kano Y, Narita T, Suzuki K et al. The effects of ICRF-154 in combination with other anticancer agents in vitro. Br J Cancer 1992;66:281-286.
21. [21] Japan Society For Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1986;21:929-942.
22. [22] Japan Society For Cancer Therapy. Criteria for the evaluation of effect reinforcement of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1986;21:943-953.
23. [23] Andoh T, Sato M, Narita T, Ishida R. Roll of DNA topoisomerase II in chromosome dynamics in mammalian cells. Biotech Appl Biochem 1993;18:165-174.
24. [24] Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 1990;26:818-821.
25. [25] The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a Working Formulation for clinical usage. Cancer 1982;49:2112-2135.